Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.
Metrics to compare | AVR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAVRPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.4x | −4.2x | −0.5x | |
PEG Ratio | 0.55 | −0.03 | 0.00 | |
Price/Book | 2.7x | 3.1x | 2.6x | |
Price / LTM Sales | 46.1x | 2.0x | 3.2x | |
Upside (Analyst Target) | - | 57.7% | 41.7% | |
Fair Value Upside | Unlock | 0.0% | 6.1% | Unlock |